Medical Condition News

RSS

Targeted reminders increase serious illness conversations in cancer care

New research in the June 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that small, targeted prompts delivered to both patients and providers at the right moment can significantly increase the number of serious illness conversations that take place.

15 Jun 2026

American Heart Association launches platform for earlier heart failure risk identification

Nearly 7 million people in the United States are living with heart failure, and that number is expected to grow in the years ahead.

15 Jun 2026

Gut cell study discovers lasting molecular scars of Crohn's disease

A detailed cellular study of Crohn’s disease has mapped how gene activity changes across more than 50 cell types in the gut.

15 Jun 2026

Blood-based indicator assesses organ age to predict disease risk

The candles on your birthday cake don't tell the whole story. As anyone who ever attended a high-school reunion can tell you, some people age faster than others.

15 Jun 2026

AI-powered deep brain stimulation improves walking in Parkinson's patients

Deep brain stimulation (DBS) has been used for more than three decades to treat motor symptoms of Parkinson's disease.

15 Jun 2026

Light-controlled molecular switch wakes lung cancer cells for treatment

Researchers from ETH Zurich have developed a molecular switch that is controlled by light. It wakes lung cancer cells up from a protective dormant state so that they are more accessible for treatment.

15 Jun 2026

Sex-dependent depression symptoms reduce healthspan in older adults

Depression is a serious mental health issue that can rob us of joy - and years of healthy living. While we know that depressive symptoms can cut down the remaining years of disability-free living (or "healthspan") in older adults, it was unclear exactly which symptoms could be the culprit.

15 Jun 2026

Novel analysis identifies unique proliferation gene alterations in diverse cancer patients

New research to be presented today (Monday) at the annual conference of the European Society of Human Genetics shows that a cancer patient's genetic ancestry can have a significant effect both on how their disease progresses and their survival. In the largest study of its kind, researchers examined nearly 1,900 specific genetic changes in tumors in order to measure whether certain mutations were more common in patients with different historic geographic origins.

15 Jun 2026

Lab trials prove copper therapy enhances cognitive function and spatial learning

Monash University researchers have found in laboratory experiments that a drug which delivers copper to the brain significantly reduces toxic Alzheimer's proteins and improves long-term spatial memory.

15 Jun 2026

Digital brain twin recreates brain activity in a toddler with autism

Researchers developed FEDE, a high-fidelity digital brain twin pipeline that combines MRI-derived anatomy with biophysical modeling to reconstruct brain structure and simulate EEG activity. In a single toddler with autism spectrum disorder, the model closely reproduced recorded brain activity and suggested possible patient-specific alterations in neural noise and excitatory-inhibitory balance.

14 Jun 2026

Glucosamine may worsen Alzheimer’s by fueling abnormal brain glycosylation

A Nature Metabolism study identifies brain hyperglycosylation as a metabolic driver of Alzheimer’s disease, with increased N-glycan biosynthesis seen in human AD tissue and mouse models. Reducing glycosylation improved memory in AD mice, while glucosamine worsened memory deficits in 5xFAD mice and was associated with poorer outcomes in dementia patients.

14 Jun 2026

Short-chain oat fiber helps steady glucose and ease gut symptoms in pilot trial

A 14-day open-label pilot study in 63 healthy adults found that short-chain oat fiber was well tolerated at doses up to 20 g/day and was associated with improved gastrointestinal symptom scores.

14 Jun 2026

Study reveals frequent stop-and-start patterns with GLP-1 drugs

People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being presented Sunday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Diabetes raises mortality risk after solid-organ transplantation

People with an organ transplant who develop or have existing diabetes are more likely to die than those without diabetes, according to a comprehensive analysis of solid-organ transplant recipients, which is being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

AI model could improve screening for primary aldosteronism

A study of a new AI model examining 30 years of routine electronic health records (EHR) data could improve screening for primary aldosteronism, a leading cause of high blood pressure that is often unrecognized but increases patients' risk of cardiovascular complications, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

New DNA test improves diagnosis of rare genetic disorders

A new test provides a much more complete picture of DNA than current standard diagnostics and leads to a diagnosis more often.

13 Jun 2026

Phase 3 study of in vivo CRISPR therapy for hereditary angioedema successfully completed

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 study of an in vivo CRISPR therapy.

13 Jun 2026

Researchers identify vulnerabilities shared by surviving cancer cells

Cancer drugs can shrink fast-growing tumors. But sometimes a few tumor cells survive. These "persister" cells seed new tumors, forcing cancer patients into arduous cycles of testing and treatment.

12 Jun 2026

FDA approves new adjuvant treatment option for ccRCC patients with recurrence risk

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

12 Jun 2026